In this regard, much is banking on Gilead Sciences, Inc., a research-based biopharmaceutical company, whose experimental drug 'remdesivir' reportedly showed positive responses in severe COVID-19- affected patients, according to reports by a medical news website STAT. The study has no control arm, with all of the patients receiving daily infusions of remdesivir. They expect results from its Phase 3 study in patients with severe COVID-19 infection at the end of this month, and additional data from other studies to become available in May. Remdesivir, which was originally tested in Ebola patients, has emerged as one of the top near-term hopes for COVID-19 patients. The 13,387 total coronavirus-positive cases in India include 11,201 active cases, 1,749 cured, discharged, or migrated patients and 437 deaths.

Source: dna April 17, 2020 05:26 UTC